Gemcitabine, Dexamethasone, And Cisplatin (GDP) Versus Dexamethasone, Cytarabine, And Cisplatin (DHAP) As Salvage Chemotherapy For Patients With Relapsed Or Refractory Non-Hodgkin's Lymphoma
Nawal Eltohamy Mohamed;
Abstract
Diffuse large B-cell lymphoma is the most common type of NHL approximately 30% of all lymphoid malignancies. It is associated with an aggressive natural history, with a median survival of less than one year in untreated patients (Flowers et al, 2010).
Other data
| Title | Gemcitabine, Dexamethasone, And Cisplatin (GDP) Versus Dexamethasone, Cytarabine, And Cisplatin (DHAP) As Salvage Chemotherapy For Patients With Relapsed Or Refractory Non-Hodgkin's Lymphoma | Other Titles | العلاج الكيمائي الچمسيتابين و السيسبلاتين والديكساميسازون بالمقارنة بالأراسى والسيسبلاتين والديكساميسازون في علاج الورم الليمفاوي المرتجع (الغير-هودجكن) | Authors | Nawal Eltohamy Mohamed | Keywords | Gemcitabine, Dexamethasone, And Cisplatin (GDP) Versus Dexamethasone, Cytarabine, And Cisplatin (DHAP) As Salvage Chemotherapy For Patients With Relapsed Or Refractory Non-Hodgkin's Lymphoma | Issue Date | 2012 | Description | Diffuse large B-cell lymphoma is the most common type of NHL approximately 30% of all lymphoid malignancies. It is associated with an aggressive natural history, with a median survival of less than one year in untreated patients (Flowers et al, 2010). |
Attached Files
| File | Size | Format | |
|---|---|---|---|
| 118720A5369.pdf | 181.6 kB | Adobe PDF | View/Open |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.